FRESENIUS KABI USA LLC
FRESENIUS KABI USA LLC
CB
At a glance
Works on
The past 12 months
Clients
1
past 12 months
Filings
2
past 12 months
Agencies contacted
Centers For Medicare and Medicaid Services (CMS)Commerce, Dept of (DOC)Defense, Dept of (DOD)Food & Drug Administration (FDA)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Labor, Dept of (DOL)Natl Economic Council (NEC)SENATEU.S. Trade Representative (USTR)White House Office
Specific issues
CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency
Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗